Table 5.
Baseline characteristics of rheumatoid arthritis (RA) patients before and after treatment of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) in cohort 4.
| Characteristics | Before treatment (n = 82) | After treatment (n = 82) |
|---|---|---|
| Female, n (%)‡ | 71 (84.51) | |
| Age (years) (mean ± SD) [min, max] | 58 ± 11 [29, 84] | |
| BMI (Kg/m2) (mean ± SD) [min, max] | 22.18 ± 6.14 [17.09, 30.18] | |
| Duration of disease (year) (mean ± SD) [min, max] | 9.47 ± 9.38 [0.50, 40.00] | |
| ESR (mm/h) (mean ± SD) [min, max] | 78.00 ± 43.03*** [10.00, 135.00] | 30.00 ± 21.91 [2.00, 80.00] |
| CRP (mg/L) (mean ± SD) [min, max] | 45.67 ± 31.94*** [1.24, 156] | 10.24 ± 15.98 [1.06, 91.60] |
| DAS28 (CRP) | 4.11 ± 1.00*** [2.36, 6.80] | 2.49 ± 0.88 [1.20, 5.00] |
| DAS28 (ESR) | 4.77 ± 1.12*** [3.20, 7.60] | 2.90 ± 1.04 [0.50, 5.10] |
| Moderate to high active RA, n | 82 | 23 |
| Low active RA, n | 0 | 26 |
| Remission RA, n | 0 | 33 |
| Rheumatoid factor, n (%) ||‡ | 67 (81.71) | 68 (82.93) |
| ACPA, n (%) ||‡ | 79 (96.34) | 79 (96.34) |
BMI, Body mass index; ESR, Erythrocyte sedimentation rate; CRP, C reactive protein; DAS28, Disease Activity Score with 28-joint counts; ACPA, anti-cyclic citrullinated peptide; (*) significance by U-test.
‡
significance by chi-square test.
||
antibody positivity.